Advances in haploidentical stem cell transplantation

Revista Brasileira de Hematologia e Hemoterapia

Volumn 33, Issue 3, 2011, Pages 237-241

  Bayraktar, Ulas Darda ^a   de Lima, Marcos ^a   Ciurea, Stefan Octavian ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bone marrow transplantation; Hematologic neoplasms; Hematopoietic stem cell transplantation; T lymphocytes immunology

Indexed keywords

EID: 80051605993     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.5581/1516-8484.20110060     Document Type: Article

References (46)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354(17):1813-26. Comment in: N Engl J Med. 2006; 355(10):1070; author reply 1070-1.
2. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med. 1998;339(17):1177-85. Erratum in: N Engl J Med. 1999;340(5):402.
3. Weisdorf DJ, Anasetti C, Antin JH, Kernan NA, Kollman C, Snyder D, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood. 2002;99(6):1971-7.
4. Kiehl MG, Kraut L, Schwerdtfeger R, Hertenstein B, Remberger M, Kroeger N, et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol. 2004;22(14):2816-25.
5. Passel JS, Wang W, Taylor P; Pew Research Center. Marrying out: one-in-seven New U.S. marriages is interracial or interethnic [Internet]. Washington (DC): Pew Research Center Publications. [cited 2011 Mar 18]. Available at: http://pewresearch.org/pubs/1616/american-marriage-interracial-interethnic
6. Falk PM, Herzog P, Lubens R, Wimmer RS, Sparkes R, Naiman JL, et al. Bone marrow transplantation between a histocompatible parent and child for acute leukemia. Transplantation. 1978;25(2):88-90.
7. Dupont B, O'Reilly RJ, Pollack MS, Good RA. Use of HLA genotypically different donors in bone marrow transplantation. Transplant Proc. 1979;11(1):219-24.
8. Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313(13):765-71.
9. Powles RL, Morgenstern GR, Kay HE, McElwain TJ, Clink HM, Dady PJ, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet. 1983;1(8325):612-5.
10. Reisner Y, Kapoor N, Kirkpatrick D, Pollack MS, Dupont B, Good RA, et al. Transplantation for acute leukeamia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells. Lancet. 1981;2(8242):327-31.
11. O'Reilly RJ, Kernan NA, Cunningham I. Allogeneic transplants depleted of T cells by soybean lectin agglutination and E-rosette depletion. Bone Marrow Transplant. 1988;3:3-6.
12. Schwartz E, Lapidot T, Gozes D, Singer TS, Reisner Y. Abrogation of bone marrow allograft resistance in mice by increased total body irradiation correlates with eradication of host clonable T cells and alloreactive cytotoxic precursors. J Immunol. 1987;138(2):460-5.
13. Terenzi A, Lubin I, Lapidot T, Salomon O, Faktorowich Y, Rabi I, et al. Enhancement of T-cell depleted bone marrow allografts in mice by thiotepa. Transplantation. 1990;50(4):717-20.
14. Cobbold SP, Martin G, Quin S, Waldmann H. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature. 1986;323(6084):164-6.
15. Reisner Y, Itzicovitch L, Meshorer A Sharon N. Hematopoietic stem cell transplantation using mouse bone-marrow and spleen cells fractionated by lectins. Proc Natl Acad Sci USA. 1978;75 (5):2933-6.
16. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, et al. Successful engraftment of T-cell-depleted haploidentical threeloci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factormobilized peripheral blood progenitor cells to bone marrow inoculum. Blood. 1994;84(11):3948-55.
17. Aversa F, Terenzi A, Tabilio A, Falzetti F, Carotti A, Ballanti S, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: A phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-54.
18. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-8.
19. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donortype CD4+CD25+ regulatory T cells suppress lethal acute graftversus- host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-99.
20. Nguyen VH, Shashidhar S, Chang DS, Ho L, Kambham N, Bachmann M, et al. The impact of regulatory T cells on T-cell immunity following hematopoietic cell transplantation. Blood. 2008;111 (2):945-53.
21. Ciurea SO, Saliba R, Rondon G, Pesoa S, Cano P, Fernandez-Vina M, et al. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010;45(3):429-36.
22. Terasaki PI, Ozawa MA. Predicting kidney graft failure by HLA antibodies a prospective trial. Am J Transplant. 2004;4(3):438-43.
23. Mao Q, Terasaki PI, Cai J, Briley K, Catrou P, Haisch C, et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant. 2007;7(4):864-71.
24. Ciurea SO, de Lima M, Cano P, Korbling M, Giralt S, Shpall EJ, et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009;88(8):1019-24.
25. Berenbaum MC, Brown IN. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature. 1963;200:84.
26. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995;85(10):2742-6.
27. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ, et al. Durable engraftment of major histocompatibility complexincompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456-64.
28. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8(7):377-86.
29. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14(6):641-50.
30. Symons H, Chen AR, Leffell MS, Zahurak M, Schultz K, Karaszkiewicz H, et al. HLA-haploidentical bone marrow transplantation (BMT) for high-risk hematological malignancies using myeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Blood (ASH Annual Meeting Abstracts) 2010;116: Abstract 2362.
31. S.O. Ciurea, R.M. Saliba, G. Rondon, M. Sharma, N. Montes, D. Bosque, et al. Haploidentical stem cell transplantation for minorities. Biol Blood Marrow Transplant 2011;17(2):s227.
32. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica. 2004;89(12):1517-24.
33. Shier LR, Schultz KR, Imren S, Regan J, Issekutz A, Sadek I, et al. Differential effects of granulocyte colony-stimulating factor on marrow- and blood-derived hematopoietic and immune cell populations in healthy human donors. Biol Blood Marrow Transplant. 2004:10(9):624-34.
34. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38:291-7.
35. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. Treatment of acute leukemia with unmanipulated HLA-mismatched/ haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant.2009;15(2):257-65.
36. Boussiotis VA, Gribben JG, Freeman GJ, Nadler LM. Blockade of the CD28 costimulatory pathway: a means to induce tolerance. Curr Opin Immunol. 1994;6(5):797-807.
37. Lin H, Bolling SF, Linsley PS, Wei RQ, Gordon D, Thompson CB, et al. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA-4Ig plus donorspecific transfusion. J Exp Med. 1993;178(5):1801-6.
38. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, et al. Transplantation of anergic histoincompatible bone marrow allografts. N Engl J Med. 1999;340(22):1704-14. Comment in: N Engl J Med. 1999;340(22):1754-6; N Engl J Med. 1999;341(14):1081-2; N Engl J Med. 1999;341(14):1082.
39. Davies JK, Gribben JG, Brennan LL, Yuk D, Nadler LM, Guinan EC. Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: Results of 2 phase I studies. Blood. 2008;112(6):2232-41.
40. Asai O, Longo DL, Tian ZG, Hornung RL, Taub DD, Ruscetti FW, et al. Suppression of graft-versus-host disease and amplification of graftversus- tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. J Clin Invest. 1998;(101):1835-42.
41. Moretta L, Locatelli F, Pende D, Marcenaro E, Mingari MC, Moretta A. Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Blood. 2011;117(3):764-71.
42. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295(5562): 2097-100. Comment in: Science. 2002;295(5562):2029-31.
43. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010;16(4):533-42.
44. Koehl U, Esser R, Zimmermann S, Tonn T, Kotchetkov R, Bartling T, et al. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children. Klin Padiatr. 2005;217(6):345-50.
45. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kühne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18(11):1835-8.
46. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45(6):1038-46.